NASDAQ:CTMX - CytomX Therapeutics Stock Price, News, & Analysis

$10.40
+0.17 (+1.66 %)
(As of 06/16/2019 04:00 PM ET)
Today's Range
$10.04
Now: $10.40
$10.54
50-Day Range
$9.35
MA: $10.39
$11.36
52-Week Range
$8.94
Now: $10.40
$27.20
Volume300,960 shs
Average Volume300,958 shs
Market Capitalization$471.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.50 million
Book Value$2.91 per share

Profitability

Net Income$-84,600,000.00
Net Margins-111.27%

Miscellaneous

Employees137
Market Cap$471.22 million
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) released its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.22. The biotechnology company earned $29.49 million during the quarter, compared to analyst estimates of $13.59 million. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

9 brokerages have issued twelve-month price targets for CytomX Therapeutics' shares. Their predictions range from $13.24 to $34.00. On average, they expect CytomX Therapeutics' share price to reach $20.9156 in the next twelve months. This suggests a possible upside of 101.1% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.

What is the consensus analysts' recommendation for CytomX Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and 12-month price target of $21/share. CytomX stock currently trades at an EV of ~$100M ($8.80/sh cash), and the shares are down about 27% YTD (vs. +8.5% for NBI), triggered by updates at its R&D day earlier this year. We believe that the company’s lead early-stage clinical assets, based on modified antibodies, are partially de-risked and are highly discounted at the current valuation. For CX-2009, we think that evolving clinical updates in the next 6-12 months should alleviate investor concerns about its safety profile and that risk of potential clinical setback is overstated." (5/13/2019)
  • 2. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/30/2019)
  • 3. HC Wainwright analysts commented, "We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $1.6B, or a price per share of $34, assuming 47.6M shares outstanding and roughly $329M in cash and equivalents as of end-4Q19." (4/3/2019)

Has CytomX Therapeutics been receiving favorable news coverage?

Media stories about CTMX stock have trended somewhat positive on Sunday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytomX Therapeutics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for CytomX Therapeutics.

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
  • Mr. Debanjan Ray, Sr. VP & CFO (Age 41)
  • Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)
  • Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
  • Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (4.72%), Victory Capital Management Inc. (3.65%), Candriam Luxembourg S.C.A. (1.48%), Pictet Asset Management Ltd. (1.35%), Spark Investment Management LLC (0.96%) and First Manhattan Co. (0.71%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Lloyd A Rowland, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FIL Ltd, Hamilton Lane Advisors LLC, TD Asset Management Inc., Los Angeles Capital Management & Equity Research Inc., Wedbush Securities Inc., Metropolitan Life Insurance Co NY and Rhumbline Advisers. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., First Manhattan Co., Spark Investment Management LLC, Candriam Luxembourg S.C.A., Acadian Asset Management LLC, Exane Asset Management, Strs Ohio and Fosun International Ltd. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $10.40.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $471.22 million and generates $59.50 million in revenue each year. The biotechnology company earns $-84,600,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.View Additional Information About CytomX Therapeutics.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is http://www.cytomx.com/.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  261 (Thanks for Voting!)
Underperform Votes:  202 (Thanks for Voting!)
Total Votes:  463
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel